Sign in Subscribe
Cancer

DNA-based Blood Test Revolutionizes Cancer Detection with High Accuracy Rates

Strategic Insights

— 2 min read

A groundbreaking DNA-based blood test, Galleri, has been revealed to have a remarkable accuracy rate of detecting over 50 types of cancer before symptoms appear. Developed by Grail, a US-based biotech company, and currently being evaluated by the UK's National Health Service (NHS), this test has the potential to transform cancer outcomes globally. In a major real-world trial, Pathfinder 2, the test showed an impressive 61.6 percent accuracy rate in detecting cancer in symptom-free individuals, with an even higher rate of accurately pinpointing the organ or tissue of origin at 92 percent.

Key Takeaways:

  • The Galleri test correctly identified cancer in 61.6 percent of people whose blood samples showed a cancer signal in the Pathfinder 2 trial.
  • The test accurately pinpointed the organ or tissue of origin in 92 percent of cancer cases detected, helping doctors determine where to look next.
  • Traditional screening methods, like mammograms or colonoscopies, target only specific cancers, whereas Galleri detects multiple cancers at once by looking for tiny fragments of tumour DNA in the blood.
  • The test led to a sevenfold increase in the number of cancers detected within a year when added to regular screening programmes in the Pathfinder 2 trial, with over 70 percent of those cancers identified at stages I to III.
  • The Galleri test's strength lies in both its scope and precision, ruling out cancer in 99.6 percent of healthy individuals and detecting the site of the tumour with remarkable accuracy.
  • For doctors, this can be a major time-saver, allowing them to quickly focus diagnostic efforts on the right part of the body.

Statistics:

  • 61.6 percent: The accuracy rate of the Galleri test in detecting cancer in symptom-free individuals in the Pathfinder 2 trial.
  • 92 percent: The accuracy rate of the Galleri test in accurately pinpointing the organ or tissue of origin in cancer cases detected.
  • 53.5 percent: The percentage of cancers caught at stage I or II, when treatment outcomes are most favourable, as a result of Galleri's addition to regular screening programmes.
  • 70 percent: The percentage of cancers identified at stages I to III before the disease had spread widely.
  • 99.6 percent: The rate at which the Galleri test can rule out cancer in healthy individuals.

Sources:

  • The Independent - Report on the Galleri blood test
  • Grail - Press release on the Pathfinder 2 trial
  • Cancer Research UK - Background on cancer screening and diagnosis
  • National Health Service (NHS) - Galleri trial details
  • Josh Ofman, president of Grail - Quote on the data from the Pathfinder 2 trial
  • Sir Harpal Kumar, president of International Business and BioPharma at Grail - Quote on the potential impact of Galleri on cancer outcomes

Read more